beat top bottom line revenu ep guidanc rais initi
guidanc double-digit ep growth vs prior eu biosimilar impact updat
steeper eros expect less
ep estim consensu full
year guidanc rais vs prior rais full
year estim manag provid initi ep
growth project doubl digit minimum dividend boost
sale estim line
consensu drug beat estim includ imbruvica
humira kaletra androgel lupron creon
combin forecast product estim includ mavyret
duodopa sevofluoran synthroid combin
light sale guidanc rais approach vs prior approach
last publish revenu estim
gpm estim
estim sg estim oper margin
estim interest/oth expens net
estim tax rate forecast share count
estim ad ep guidanc gpm
intact oper margin vs prior
four humira biosimilar launch eu mid-octob indic initi
discount high-end expect discount rang
nordic countri ou volum manag expect
eros larg less vs prior expect
two year humira ou sale guidanc lower approxim vs
prior approxim sale guidanc unchang
imbruvica ph ii data pancreat cancer resolv imbruvica rituxan eu approv
wm venclexta w/roch approv aml pdufa upadacitinib file
ra orilissa elagolix full ph data uterin fibroid posit top-lin veliparib ph
data vela non-sq nsclc emplic w/bmi approv r/r mm w/poma dex
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani pipelin promis
agent opportun upward revis sever front stock
attract valu versu group overal attribut argu purchas
upadacitinib /eu file ra
risankizumab approv psoriasi
venclexta approv aml
humira sale
humira biosimilar eros less
especi oncolog
humira biosimilar gain traction
quickli eu and/or launch
global biopharmaceut compani product use treat rheumatoid
chronic kidney diseas among other humira ra crohn domin
product repres total sale profit also pipelin
compound indic phase ii phase develop
cowen compani
chg total good profit margin profit gross gross profit profit gross gross profit oper foreign exchang gain expens incom expens incom share cowen
cowen compani
reportedour estimatedifferenceproduct exceed cowen
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock roch hold ltd adr secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
